Use of community-based, directly observed therapy for HIV infection: Lessons learned for treatment of hepatitis C virus infection

Clinical Infectious Diseases

Volumn 40, Issue SUPPL. 5, 2005, Pages

  Flanigan, Timothy P ^a,b   Taylor, Lynn E ^a   Mitty, Jennifer A ^a  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

ADDICTION; ADULT; CASE REPORT; CONFERENCE PAPER; DRUG DEPENDENCE; FEMALE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SOCIAL PSYCHOLOGY; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DELIVERY OF HEALTH CARE; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; PILOT PROJECTS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 16844385262     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427451     Document Type: Conference Paper

References (14)

1. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274:945-51.
2. Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333:229-33.
3. El-Sadr W, Medard F, Barthand V. Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. Am J Public Health 1996; 86:1146-9.
4. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342:921-9.
5. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-8.
6. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36(Suppl 5B):S93-8.
7. McHutchison J, Patel K. Future therapy of hepatitis C. Hepatology 2002; 36(Suppl 5B):S245-52.
8. Mitty JA, McKenzie M, Stenzel M, et al. Modified directly observed therapy for treatment of human immunodeficiency virus [letter]. JAMA 1999; 282:1334.
9. Stenzel MS, McKenzie M, Mitty JA, Flanigan TP. Enhancing adherence to HAART: a pilot program modified directly observed therapy. AIDS Read 2001; 11:317-9, 324-8.
10. Clarke S, Keenan E, Ryan M, et al. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read 2002; 12:305-7, 312-6.
11. McCance-Katz EF, Gourevitch MN, Arnstein J, et al. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict 2002; 11:271-8.
12. Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed therapy. Clin Infect Dis 2002; 34:511-8.
13. Adelson Mitty J, Stone VE, Sands M, Macalino G, Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002; 34:984-90.
14. Mitty JA, Macalino GE, McKenzie M, et al. Directly observed therapy (DOT) among HIV seropositive substance users: a pilot study [abstract 707]. In: Program and abstracts of the 39th annual meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001:1209.